Company Overview

Neuralieve, a privately held medical technology company, is pioneering portable, non-invasive Transcranial Magnetic Stimulation (TMS) devices for treating neurological conditions. The proprietary technology will first be used in the development of a device to treat migraine headache. Prescribed by physicians but designed for patient use, it is being developed as the first truly portable, convenient TMS product that will allow migraine patients to administer treatment as needed—at home, in the office or on the go.

The Neuralieve investigational device is placed at the back of the head for less than a minute, generating a focused, single magnetic pulse that induces a mild electric current in the back of the brain. Leaders in the field of headache medicine believe this targeted signal depolarizes—or short circuits—the hyper-excitability in areas of the brain associated with migraine and the abnormal brainwaves typical in cortical spreading depression (CSD), which is associated with migraine aura.

Used for many years as a non-invasive method of diagnosing and studying brain activity, recent scientific evidence has demonstrated TMS is also an effective tool in treating neurological disorders. Neuralieve technology uses single pulse TMS, or sTMS, which is considered very safe. In fact, FDA classified sTMS as a non-significant risk over ten years ago. The magnetic field is approximately half the strength of a typical MRI device and patients do not feel the mild electric current stimulated by the sTMS Device.

CAUTION: Investigational Device. Federal or (United States) law limits device to investigational use.